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Table 1: Relapse rates in patients with MC and FD chimerism in whole BM,
PB, and subsets
Chimerism N* Mixed chimerism
(MC)
Full donor
chimerism (FDC)
EFS
N with
MC
Relapse
rate in
pts with
MC
N with
FDC
Relapse
rate in
pts with
FDC
Log
Rank
P value
Whole BM 39 26 35% 13 15% 0.1
BM - CD3 subset 29 24 25% 5 0% 0.09
BM - Leukemia
speciﬁc subset
33 17 35% 16 6% 0.002
BM- CD34 subset 31 21 33% 10 10% 0.04
All BM subsets 37 30 33% 7 0% 0.03
Whole PB 42 22 32% 20 25% 0.8
PB -CD3 subset 42 31 32% 11 18% 0.6
PB - Leukemia
speciﬁc subset
42 19 26% 23 30% 0.8
All PB subsets 43 35 34% 8 12% 0.14
* Number of patients who had early post-HCT chimerism test done on a
speciﬁc subset.
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fusions (DLI) in children receiving HCT for leukemia. We
enrolled 43 patients. Donors and stem cell sources
included matched related (49%), matched unrelated (30%)
and mismatched unrelated donors (21%) of BM (53%) and
peripheral blood (PB) (47%). Chimerism analyses on whole
PB and BM and subsets were done using a semi-quanti-
tative PCR-based method (1% sensitivity), on day
32.5SD8 (PB) and day3810 (BM). If mixed chimerism
(MC) was found in any PB or BM subset on 2 tests, FWI
over 2-4 weeks was initiated, followed by DLI if MC per-
sisted. The end point for IT was full donor (FD) chimerism
in all PB subsets or development of GVHD. Patients with
GVHD or FD chimerism in all subsets were assigned to the
observation group (N¼12); patients with MC in any subset
were assigned to the IT group (N¼26). 15 patients received
FWI and DLI and 11 received FWI only. Five patients could
not be assigned to either group due to early toxic death
(N¼1) or relapse (N¼4). Follow-up of living patients is
28.89.7 months. Events included relapse (N¼13) and
toxic death (N¼2), one of which was intervention related,
resulting in 4% treatment-related mortality. Estimated 36-
mos EFS is 8310% for the observation group, 5414% for
the IT group and 5610% for the entire cohort, including
unassigned patients. Acute and/or chronic GVHD devel-
oped in 5/26 (19%) patients following IT. Residual disease
(RD) prior to HCT remained a predictor of EFS. Despite IT
7/11 patients with RD and 6/26 without, developed
relapse (Log Rank p<0.001). Early post-HCT BM chime-
rism was better predictor of EFS than PB chimerism (Table
1). We recommend that post-HCT IT continues until 100%
chimerism in all BM subsets is achieved.90
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Angeles, CABackground: Genetic lymphohematopoietic diseases have
been effectively cured by performing allogeneic blood and
marrow transplant (BMT) from a histocompatible sibling,
following a standard conditioning regimen with busulfan
(BU), cyclophosphamide (CY), and antithymocyte globulin
(ATG). However, the high levels of transplant related mor-
tality (TRM) and morbidity with this regimen limits its more
widespread use as curative therapy.
Objective: To determine the safety, donor chimerism and
complications associated with de-escalation of CY, in a
reduced toxicity conditioning regimen with ﬂudarabine and
alemtuzumab, prior to HLA-matched sibling donor trans-
plantation among pediatric recipients with genetic lym-
phohematopoietic diseases.
Methods: Eligible patients were consented at Children’s
Hospital Los Angeles, Stanford Hospital and Lucile Packard
Children’s Hospital between 2008 and 2013. The condition-
ing regimen consisted of Busulfan 16 mg/kg, Cyclophospha-
mide 105mg/m2 Fludarabine 105mg/m2, and Alemtuzumab
52mg/m2. Graft versus host disease prophylaxis consisted of
steroids and a calcineurin inhibitor.
Results: The study population was 68% female with a me-
dian age of 5.25 ( 5.9 years). Patients pre-transplant di-
agnoses included Sickle Cell Disease (n¼7), Thalassemia
(n¼4); Kostmann’s Syndrome (n¼2), Chronic Granuloma-
tous Disease (n¼1), Chediak Higashi syndrome (n¼1),
hemophagocytic lymphohistiocytosis (n¼2), Cartilage Hair
Hypoplasia (n¼1), Diamond Blackfan Anemia (n¼2), and
Hurler’s syndrome (n¼2). The median total nucleated cell
count (TNC) and CD34 dose was 4.6x108 ( 2.26x108) cells/
kg and 8.5x106 ( 5.2x106) cells/kg respectively. All pa-
tients had an initial donor chimerism >90% (median 99%).
The median time to neutrophil engraftment (>500 cells/
mL) and platelet engraftment (>20K cells/microliter) were
19 (9.7) and 23.5 ( 26.2) days respectively. One patient
required a stem cell boost on day +83 (poor count recovery
due to CMV). There were no cases of veno-occlussive dis-
ease or Grade III/IV acute or extensive chronic GVHD. In-
fectious complications (Figure 2) included CMV viremia
(n¼5), EBV viremia (n¼1), mucoromycosis (n¼1) and
adenoviremia (n¼1); two patients expired, one from
pneumonitis (EBV viremia) and the other from mucormy-
cosis. Overall survival (OS) at 100 days was 95%; with a
median follow up of 1 ( 2.05) years, the OS is 90%, with all
patients sustaining high-level donor chimerism and a
median Lansky/Karnofsky score of 100. Conclusion: A
reduced toxicity conditioning regimen with reduced doses
of CY achieves durable engraftment of stem cells from
related donors among patients with genetic lymphohe-
matopoietic diseases and low rates of transplant related
mortality and morbidity. Longer follow-up is required to
assess for a potential reduction in late effects associated
with this regimen.
